AU
UK
CA
US
IND
NZ
Last update at 2026-06-03T20:00:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Silence Therapeutics plc (SLN): Among Takeover Rumors Hedge Funds Are Buying
Thu 24 Apr 25, 01:24 AMThe 3 Best Gene Editing Stocks to Buy in August 2024
Wed 07 Aug 24, 01:00 PMMorgan Stanley Predicts Triple-Digit Rally for These 3 Stocks
Thu 25 Jul 24, 12:00 AM7 Biotech Stocks Ready to Ride the Sector’s Resurgence
Tue 19 Mar 24, 12:01 AM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -47.36800M | -45.85600M | -36.04100M | -22.87000M | -20.52600M |
| Minority interest | - | - | - | - | - |
| Net income | -40.48900M | -39.41000M | -32.54700M | -19.58200M | -18.41100M |
| Selling general administrative | 19.61M | 20.01M | 13.98M | 9.64M | 10.83M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 6.62M | 4.96M | 1.72M | 0.24M | - |
| Reconciled depreciation | 0.48M | 0.43M | 0.50M | 0.48M | 0.40M |
| Ebit | -48.59300M | -45.81400M | -35.84700M | -22.73400M | -20.57100M |
| Ebitda | -47.88500M | -45.37700M | -35.22200M | -22.22500M | -20.17200M |
| Depreciation and amortization | 0.71M | 0.44M | 0.62M | 0.51M | 0.40M |
| Non operating income net other | - | - | - | - | - |
| Operating income | -48.59300M | -45.81400M | -35.84700M | -22.73400M | -20.57100M |
| Other operating expenses | 66.09M | 58.23M | 41.33M | 22.98M | 20.57M |
| Interest expense | 0.05M | 0.00800M | 0.32M | 0.16M | 0.04M |
| Tax provision | -6.87900M | -6.44600M | -4.60000M | -3.28800M | -2.11500M |
| Interest income | 0.23M | 0.01000M | 1.73M | 0.03M | 0.04M |
| Net interest income | 0.18M | 0.00200M | 1.73M | -0.00600M | 0.04M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | -6.87900M | -6.44600M | -3.49400M | -3.28800M | -2.11500M |
| Total revenue | 17.50M | 12.41M | 5.48M | 0.24M | 0.00000M |
| Total operating expenses | 55.21M | 50.77M | 37.56M | 22.98M | 20.57M |
| Cost of revenue | 10.88M | 7.46M | 3.76M | - | - |
| Total other income expense net | 1.23M | -0.04200M | -0.19400M | -0.13600M | 0.00600M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -40.48900M | -39.41000M | -22.05800M | -19.58200M | -18.41100M |
| Net income applicable to common shares | -40.48900M | -39.41000M | -32.54700M | -19.58200M | -18.41100M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 93.82M | 107.50M | 96.19M | 85.97M | 46.08M |
| Intangible assets | 0.28M | 0.32M | 0.02M | 0.02M | 0.03M |
| Earning assets | - | - | - | - | - |
| Other current assets | 26.76M | - | 4.31M | 4.62M | 0.89M |
| Total liab | 76.77M | 85.43M | 87.67M | 76.91M | 25.17M |
| Total stockholder equity | 17.05M | 22.07M | 8.53M | 9.06M | 20.91M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 9.80M | 9.45M | 6.72M | 5.91M | 5.10M |
| Common stock | 5.94M | 5.39M | 4.49M | 4.17M | 3.92M |
| Capital stock | 5.94M | 5.39M | 4.49M | 4.17M | 3.92M |
| Retained earnings | -304.61200M | -263.26300M | -222.96600M | -184.21500M | -151.99900M |
| Other liab | - | 63.48M | 72.50M | 51.34M | 15.52M |
| Good will | 7.84M | 8.01M | 7.59M | 8.12M | 7.69M |
| Other assets | - | - | - | - | - |
| Cash | 54.03M | 54.82M | 73.54M | 27.45M | 13.52M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 17.77M | 21.94M | 15.17M | 25.57M | 9.65M |
| Current deferred revenue | 5.16M | 8.86M | 4.25M | 17.04M | 2.48M |
| Net debt | -53.75900M | -54.37000M | -73.40000M | -27.10800M | -13.22800M |
| Short term debt | 0.18M | 0.45M | 0.14M | 0.34M | 0.29M |
| Short long term debt | - | - | - | - | - |
| Short long term debt total | 0.27M | 0.45M | 0.14M | 0.34M | 0.29M |
| Other stockholder equity | 291.52M | 255.61M | 203.21M | 9.06M | 171.94M |
| Property plant equipment | - | 2.20M | 1.94M | 1.13M | 0.61M |
| Total current assets | 81.02M | 96.69M | 86.33M | 76.40M | 37.47M |
| Long term investments | 0.28M | 0.28M | 0.30M | 0.30M | - |
| Net tangible assets | - | 13.74M | 0.91M | 0.92M | 13.18M |
| Short term investments | 0.00000M | 16.33M | - | 10.00M | 20.00M |
| Net receivables | 18.83M | 17.34M | 8.49M | 32.84M | 3.06M |
| Long term debt | - | - | - | - | - |
| Inventory | -18.60500M | - | - | 1.49M | - |
| Accounts payable | 2.63M | 3.19M | 4.07M | 8.19M | 6.89M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | 24.20M | 24.33M | 23.79M | 189.11M | 168.99M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | 4.17M | 3.92M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 2.58M | - | - | 10.00M | 20.00M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 12.80M | 10.81M | 9.86M | 9.57M | 8.61M |
| Capital lease obligations | 0.27M | 0.45M | 0.14M | 0.34M | 0.29M |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -16.54200M | 10.00M | -41.25400M | -15.01500M | -4.83000M |
| Change to liabilities | -3.45400M | 10.77M | 51.69M | 21.05M | 1.15M |
| Total cashflows from investing activities | -16.54200M | 8.68M | 9.62M | -15.01500M | -4.83000M |
| Net borrowings | -0.19000M | -0.21100M | -0.40200M | -0.40200M | -0.40200M |
| Total cash from financing activities | 43.05M | 30.71M | 15.43M | 5.27M | 0.34M |
| Change to operating activities | -4.22500M | 0.59M | -3.73000M | 0.04M | -0.92400M |
| Net income | -47.36800M | -45.85600M | -36.04100M | -22.87000M | -20.52600M |
| Change in cash | -18.72100M | 46.09M | 13.93M | -7.97900M | -21.25100M |
| Begin period cash flow | 73.54M | 27.45M | 13.52M | 21.49M | 42.74M |
| End period cash flow | 54.82M | 73.54M | 27.45M | 13.52M | 21.49M |
| Total cash from operating activities | -45.45600M | 6.81M | -10.77600M | 1.73M | -16.76000M |
| Issuance of capital stock | 43.24M | 30.92M | 15.83M | 5.27M | 0.34M |
| Depreciation | 0.48M | 0.43M | 0.50M | 0.48M | 0.40M |
| Other cashflows from investing activities | 0.02M | 0.01000M | 0.13M | -0.00600M | 0.04M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | - | - | - | - | - |
| Change to account receivables | -0.58400M | 27.48M | -29.30200M | -0.00400M | 0.69M |
| Sale purchase of stock | - | - | - | - | 0.00000M |
| Other cashflows from financing activities | -16.54200M | 8.68M | 9.62M | -15.01500M | -4.83000M |
| Change to netincome | 2.81M | 6.94M | 7.48M | -0.25800M | 0.34M |
| Capital expenditures | 0.44M | 1.33M | 0.51M | 0.00900M | 0.19M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | -8.26300M | 38.84M | 18.66M | 21.09M | 0.91M |
| Stock based compensation | 10.25M | 8.63M | 4.39M | 0.58M | 0.68M |
| Other non cash items | -0.55900M | 0.35M | -4.67000M | 0.14M | -0.04500M |
| Free cash flow | -45.89600M | 5.47M | -11.29000M | 1.72M | -16.94800M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| SLN Silence Therapeutics PLC |
0.04 0.63% | 6.41 | - | - | 43.41 | 48.26 | 40.77 | -20.7846 |
| NVO Novo Nordisk A/S |
-0.92 2.14% | 42.00 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
-0.75 1.73% | 42.50 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
3.25 0.76% | 428.34 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
| REGN Regeneron Pharmaceuticals Inc |
16.03 2.66% | 618.95 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver. The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease associated with elevated lipoprotein(a); and Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera. It is also developing SLN-COMP-1 and SLN-COMP-2 for complement-mediated diseases; and SLN-HAN-1 and SLN-HAN-2. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.
72 Hammersmith Road, London, United Kingdom, W14 8TH
| Name | Title | Year Born |
|---|---|---|
| Mr. Craig A. Tooman M.B.A., MBA | Pres, CEO & Exec. Director | 1966 |
| Ms. Rhonda L. Hellums | Chief Financial Officer | 1972 |
| Dr. Giles V. Campion M.D. | Exec. VP, Head of R&D, Chief Medical Officer and Exec. Director | 1954 |
| Ms. Gem Gokmen Hopkins | Head of IR & Corp. Communications | NA |
| Dr. John Strafford Ph.D. | Sr. VP of Bus. Devel., Alliance Management & New Product Devel. | NA |
| Mr. Jørgen Wittendorff | Sr. VP & Head of Manufacturing | NA |
| Dr. Barbara A. Ruskin J.D., Ph.D. | Sr. VP and Chief Intellectual Property & Innovation Officer | 1960 |
| Dr. Eric Floyd Ph.D. | Sr. VP of Regulatory Affairs & Quality Assurance | 1962 |
| Dr. Marie Wikstrom Lindholm Ph.D. | Sr. VP & Head of Molecular Design | NA |
| Mr. Craig A. Tooman M.B.A. | President, CEO & Executive Director | 1965 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Please wait processing your request...